Exicure, Inc. (the Company) announced as previously disclosed, on July 30, 2021, the company entered into a Collaboration, Option and License Agreement with (the Ipsen Collaboration Agreement) with Ipsen Biopharm Limited (the Ipsen), pursuant to which the company granted to Ipsen exclusive access and options to license SNA-based therapeutics arising from two collaboration programs related to the treatment of Huntington's disease and Angelman syndrome. On December 12, 2022, the company and Ipsen entered into a Mutual Termination Agreement (the Ipsen Termination Agreement), pursuant to which the parties mutually agreed to terminate the Ipsen Collaboration Agreement. Following such termination, the parties will jointly own R&D Term IP and Patents Covering the R&D Term IP, with each party owning an equal, undivided interest in and to such R&D Term IP and patents.

Termination of AbbVie Collaboration Agreement: On November 13, 2019, the company entered into a Collaboration, Option and License Agreement (the AbbVie Collaboration Agreement), with Allergan Pharmaceuticals International Limited (Allergan). On May 8, 2020, Allergan plc, including Allergan was acquired by AbbVie Inc. (AbbVie). Pursuant to the AbbVie Collaboration Agreement, the company granted to AbbVie exclusive access and options to license SNA-based therapeutics arising from two collaboration programs related to the treatment of hair loss disorders.

On December 13, 2022, the company and Allergan entered into a letter agreement (the AbbVie Termination Agreement), pursuant to which the parties mutually agreed to terminate the AbbVie Collaboration Agreement. Following such termination, the Company will transfer to Allergan all data, information, and reports made or generated by the Company in the course of performing activities under the Development Plan (as defined in the AbbVie Collaboration Agreement), and grant to Allergan all rights to transfer, publish, present, or otherwise publicly disclose any Collaboration Technology (as defined in the AbbVie Collaboration Agreement) and data made or generated by the Company in the course of performing activities under the Development Plan. As a result of the respective terminations of the Ipsen Collaboration Agreement and the AbbVie Collaboration Agreement, the company regains the ability to independently develop medicines targeting hair loss disorders, Angelman syndrome, and Huntington's disease whilst Ipsen retains the right to re-enter into the collaboration with the Company in Huntington's Disease and Angelman's Syndrome.